Annovis Bio Inc (ANVS)

Apr 26, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 26, 2025

Apr 21, 2025

Annovis Bio, Inc. (NYSE:ANVS) Receives Average Recommendation of “Buy” from Analysts - Defense World

Apr 21, 2025

Apr 09, 2025

Annovis Bio stock plunges to 52-week low of $1.14 By Investing.com - Investing.com Canada

Apr 09, 2025

Apr 09, 2025

Annovis Bio stock plunges to 52-week low of $1.14 - Investing.com

Apr 09, 2025

Apr 09, 2025

Buntanetap shows early potential for Parkinson’s-related dementia - The Pharma Letter

Apr 09, 2025

Apr 08, 2025

Parkinson's Disease Pipeline Analysis and Clinical Trials - openPR.com

Apr 08, 2025

Apr 03, 2025

Buntanetap for Parkinson’s disease - Parkinson's News Today

Apr 03, 2025

Apr 02, 2025

Annovis Bio to Showcase Advancements at Alzheimer’s & Parkinson’s Drug Development Summit - MSN

Apr 02, 2025

Mar 31, 2025

Annovis Bio stock hits 52-week low at $1.52 amid sharp decline By Investing.com - Investing.com South Africa

Mar 31, 2025

Mar 31, 2025

Annovis Bio stock hits 52-week low at $1.52 amid sharp decline - Investing.com India

Mar 31, 2025

Mar 31, 2025

Annovis Bio Receives Non-Compliance Notice from NYSE - MSN

Mar 31, 2025

Mar 30, 2025

Annovis Bio to Present Promising Data on Buntanetap at AD/PD™ 2025 - MSN

Mar 30, 2025

Mar 27, 2025

Annovis Bio faces NYSE delisting over market cap, equity shortfall By Investing.com - Investing.com South Africa

Mar 27, 2025

Mar 27, 2025

Annovis Bio Gets NYSE Noncompliance Notice - MarketScreener

Mar 27, 2025

Mar 27, 2025

Annovis Bio Faces NYSE Non-Compliance Notice - TipRanks

Mar 27, 2025

Mar 27, 2025

Annovis Bio faces NYSE delisting over market cap, equity shortfall - Investing.com

Mar 27, 2025

Mar 27, 2025

Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE - GlobeNewswire

Mar 27, 2025

Mar 27, 2025

NYSE Warning: Annovis Bio Must Submit 45-Day Survival Plan as Market Cap Plunges - Stock Titan

Mar 27, 2025

Mar 26, 2025

Annovis to Attend AD/PD™ 2025 with Extensive Scientific Program - GlobeNewswire

Mar 26, 2025

Mar 25, 2025

Stocks In Spotlight: ANVS, PTN, AVIR, IRWD, FGEN, ACAD - RTTNews

Mar 25, 2025

Mar 25, 2025

Annovis Bio Reports Progress in Clinical Trials and Improved Financial Position - MSN

Mar 25, 2025

Mar 25, 2025

Agitation in Alzheimer's Disease Market: Analysis - openPR.com

Mar 25, 2025

Mar 25, 2025

Annovis Bio Inc. to Present Key Findings at AD/PD™ 2025 Conference in Vienna on Alzheimer's and Parkinson's Treatments - Nasdaq

Mar 25, 2025

Mar 25, 2025

Game-Changing Phase 3 Results: Annovis Reveals Dual Breakthrough in Parkinson's and Alzheimer's Treatment - Stock Titan

Mar 25, 2025

Mar 21, 2025

Annovis Bio Inc. (ANVS) reports earnings - Quartz

Mar 21, 2025

Mar 21, 2025

Annovis Bio, Inc. SEC 10-K Report - TradingView

Mar 21, 2025

Mar 21, 2025

Annovis Provides Corporate Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results - The Manila Times

Mar 21, 2025

Mar 21, 2025

Annovis Bio Inc. Reports Corporate Updates and Financial Results for Fourth Quarter and Full Year 2024 - Nasdaq

Mar 21, 2025

Mar 11, 2025

Annovis Bio stock hits 52-week low at $1.55 amid sharp decline - Investing.com Australia

Mar 11, 2025

Mar 11, 2025

Annovis Joins Experts at Drug Development Summit to Redefine Parkinson's Treatment - GlobeNewswire

Mar 11, 2025

Mar 11, 2025

Revolutionary Parkinson's Treatment: Annovis Unveils Phase III Data for Multi-Target Drug - StockTitan

Mar 11, 2025

Mar 03, 2025

LEQEMBI Market Sales Reflect Growing Confidence in Disease-Modifying Alzheimer’s Treatments| DelveInsight - GlobeNewswire Inc.

Mar 03, 2025

Mar 03, 2025

Atria Wealth Solutions Inc. Purchases Shares of 13,002 Annovis Bio, Inc. (NYSE:ANVS) - Defense World

Mar 03, 2025

Mar 01, 2025

Annovis Bio stock hits 52-week low at $1.72 amid market challenges - Investing.com Australia

Mar 01, 2025

Feb 28, 2025

ANVS ALERTLabaton Sucharow Announces the Filing of a Securities Class Action Against Annovis Bio, Inc.; Investors Encouraged to Contact the Firm Before October 18 - ACCESS Newswire

Feb 28, 2025

Feb 28, 2025

Annovis Bio stock hits 52-week low at $1.72 amid market challenges By Investing.com - Investing.com South Africa

Feb 28, 2025